Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dihydrohydroxycodeinone
2. Dihydrone
3. Dinarkon
4. Eucodal
5. Oxiconum
6. Oxycodeinon
7. Oxycodone
8. Oxycone
9. Oxycontin
10. Pancodine
11. Theocodin
1. 124-90-3
2. Oxycodone Hcl
3. Oxecta
4. Oxycontin
5. Endocodone
6. Roxicodone
7. Oxycodone Hydrochloride Cii
8. Chebi:7859
9. 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one Hydrochloride
10. (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride
11. (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydron;chloride
12. Roxicodone (tn)
13. Oxycontin (tn)
14. (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride
15. Oxecta (tn)
16. Roxybond
17. Oxycodone Monohydrochloride
18. Schembl30095
19. Oxycodone Hydrochloride (usp)
20. Chembl1200890
21. Dtxsid80924674
22. Oxycodone Hydrochloride [mi]
23. Oxycodone Hydrochloride [usan]
24. Akos024457896
25. Oxycodone Hydrochloride [mart.]
26. Oxycodone Hydrochloride [vandf]
27. Anhydrous Oxycodone Hydrochloride
28. Oxycodone Hydrochloride [who-dd]
29. Oxycodone Hydrochloride, Analytical Standard
30. Oxycodone Hydrochloride [orange Book]
31. Oxycodone Hydrochloride Cii [usp-rs]
32. Oxycodone Hydrochloride [ep Monograph]
33. Tylox Component Oxycodone Hydrochloride
34. C08026
35. Codoxy Component Oxycodone Hydrochloride
36. D00847
37. Oxycet Component Oxycodone Hydrochloride
38. Oxycodone Hydrochloride [usp Monograph]
39. Roxicet Component Oxycodone Hydrochloride
40. Roxilox Component Oxycodone Hydrochloride
41. Troxyca Component Oxycodone Hydrochloride
42. Combunox Component Oxycodone Hydrochloride
43. Oxycodone Hydrochloride Component Of Tylox
44. Percocet Component Oxycodone Hydrochloride
45. Percodan Component Oxycodone Hydrochloride
46. Roxiprin Component Oxycodone Hydrochloride
47. Targiniq Component Oxycodone Hydrochloride
48. Xartemis Component Oxycodone Hydrochloride
49. Oxycodone Hydrochloride Component Of Codoxy
50. Oxycodone Hydrochloride Component Of Oxycet
51. Oxycodone Hydrochloride Component Of Roxicet
52. Oxycodone Hydrochloride Component Of Roxilox
53. Oxycodone Hydrochloride Component Of Troxyca
54. Oxycodone Hydrochloride Component Of Combunox
55. Oxycodone Hydrochloride Component Of Percocet
56. Oxycodone Hydrochloride Component Of Percodan
57. Oxycodone Hydrochloride Component Of Roxiprin
58. Oxycodone Hydrochloride Component Of Targiniq
59. Oxycodone Hydrochloride Component Of Xartemis
60. Percodan-demi Component Oxycodone Hydrochloride
61. Q27107601
62. Oxycodone Hydrochloride Component Of Percodan-demi
63. 14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one Hydrochloride
64. Oxycodone Hydrochloride, European Pharmacopoeia (ep) Reference Standard
65. Oxycodone Hydrochloride, United States Pharmacopeia (usp) Reference Standard
66. (5?)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one Hydrochloride
67. (5alpha,17s)-14-hydroxy-3-methoxy-17-methyl-6-oxo-4,5-epoxymorphinan-17-ium Chloride
68. 4,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one Hydrochloride
69. Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, Hydrochloride, (5.alpha.)-
70. Oxycodone Hydrochloride Solution, 1.0 Mg/ml In Methanol, Analytical Standard, For Drug Analysis
Molecular Weight | 351.8 g/mol |
---|---|
Molecular Formula | C18H22ClNO4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 1 |
Exact Mass | 351.1237359 g/mol |
Monoisotopic Mass | 351.1237359 g/mol |
Topological Polar Surface Area | 59 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 553 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Oxecta |
Drug Label | OXECTA (oxycodone HCl, USP) tablets are an immediate-release opioid analgesic intended for oral administration only. OXECTA contains oxycodone HCl, USP as the active analgesic ingredient. The tablets are round, convex, white and debossed with the str... |
Active Ingredient | Oxycodone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 5mg |
Market Status | Prescription |
Company | Acura Pharms |
2 of 4 | |
---|---|
Drug Name | Oxycodone hydrochloride |
Drug Label | DESCRIPTIONOxyContin (oxycodone hydrochloride controlled-release) Tablets are an opioid analgesic supplied in 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, and 160 mg tablet strengths for oral administration... |
Active Ingredient | Oxycodone hydrochloride |
Dosage Form | Tablet, extended release; Tablet; Capsule; Solution |
Route | oral; Oral |
Strength | 30mg; 100mg/5ml; 15mg; 5mg; 10mg; 5mg/5ml; 80mg; 40mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Corepharma; Vintage Pharms; Amneal Pharms; Impax Pharms; Aurolife Pharma; Avanthi; Teva; Endo Pharms; Sun Pharm Inds; Coastal Pharms; Rhodes Pharms; Mallinckrodt; Roxane; Lannett Holdings; Nesher Pharms; Vistapharm; Actavis Elizabeth; Lehigh Valley; Alvog |
3 of 4 | |
---|---|
Drug Name | Oxecta |
Drug Label | OXECTA (oxycodone HCl, USP) tablets are an immediate-release opioid analgesic intended for oral administration only. OXECTA contains oxycodone HCl, USP as the active analgesic ingredient. The tablets are round, convex, white and debossed with the str... |
Active Ingredient | Oxycodone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 5mg |
Market Status | Prescription |
Company | Acura Pharms |
4 of 4 | |
---|---|
Drug Name | Oxycodone hydrochloride |
Drug Label | DESCRIPTIONOxyContin (oxycodone hydrochloride controlled-release) Tablets are an opioid analgesic supplied in 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, and 160 mg tablet strengths for oral administration... |
Active Ingredient | Oxycodone hydrochloride |
Dosage Form | Tablet, extended release; Tablet; Capsule; Solution |
Route | oral; Oral |
Strength | 30mg; 100mg/5ml; 15mg; 5mg; 10mg; 5mg/5ml; 80mg; 40mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Corepharma; Vintage Pharms; Amneal Pharms; Impax Pharms; Aurolife Pharma; Avanthi; Teva; Endo Pharms; Sun Pharm Inds; Coastal Pharms; Rhodes Pharms; Mallinckrodt; Roxane; Lannett Holdings; Nesher Pharms; Vistapharm; Actavis Elizabeth; Lehigh Valley; Alvog |
Analgesics, Opioid
Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)
Narcotics
Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-06-21
Pay. Date : 2014-06-13
DMF Number : 18472
Submission : 2005-06-30
Status : Active
Type : II
Certificate Number : CEP 2005-036 - Rev 04
Issue Date : 2024-04-10
Type : Chemical
Substance Number : 1793
Status : Valid
NDC Package Code : 49812-0150
Start Marketing Date : 2010-06-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Baeksu Pharmaceutical Co., Ltd.
Registration Date : 2019-12-23
Registration Number : 20191223-209-J-267(A)
Manufacturer Name : Macfarlan Smith Limited
Manufacturer Address : 10 Wheatfield Road, Edinburgh, EH11 2QA, United Kingdom
Available Reg Filing : ROW, CN |
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
Date of Issue : 2018-02-19
Valid Till : 2019-02-19
Written Confirmation Number : 665/149786
Address of the Firm :
Certificate Number : CEP 2008-249 - Rev 03
Issue Date : 2024-03-01
Type : Chemical
Substance Number : 1793
Status : Valid
Available Reg Filing : CN |
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-16
Pay. Date : 2013-04-05
DMF Number : 16399
Submission : 2003-02-03
Status : Active
Type : II
Certificate Number : R1-CEP 2009-058 - Rev 04
Issue Date : 2022-05-12
Type : Chemical
Substance Number : 1793
Status : Valid
NDC Package Code : 51634-0002
Start Marketing Date : 2000-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Samung Industrial Co., Ltd.
Registration Date : 2024-01-26
Registration Number : 20240126-209-J-1599
Manufacturer Name : Noramco, LLC
Manufacturer Address : 500 Swedes Landing Road Wilmington, Delaware 19801
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32506
Submission : 2018-03-16
Status : Active
Type : II
NDC Package Code : 49812-0150
Start Marketing Date : 2010-06-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Baeksu Pharmaceutical Co., Ltd.
Registration Date : 2019-12-23
Registration Number : 20191223-209-J-267(A)
Manufacturer Name : Macfarlan Smith Limited
Manufacturer Address : 10 Wheatfield Road, Edinburgh, EH11 2QA, United Kingdom
Available Reg Filing : ROW, CN |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34028
Submission : 2019-10-14
Status : Active
Type : II
NDC Package Code : 49812-0150
Start Marketing Date : 2010-06-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Baeksu Pharmaceutical Co., Ltd.
Registration Date : 2019-12-23
Registration Number : 20191223-209-J-267(A)
Manufacturer Name : Macfarlan Smith Limited
Manufacturer Address : 10 Wheatfield Road, Edinburgh, EH11 2QA, United Kingdom
Available Reg Filing : ROW, CN |
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Reviewed
Rev. Date : 2012-12-27
Pay. Date : 2012-11-23
DMF Number : 20975
Submission : 2007-10-26
Status : Active
Type : II
Certificate Number : R1-CEP 2011-284 - Rev 02
Issue Date : 2021-02-24
Type : Chemical
Substance Number : 1793
Status : Valid
NDC Package Code : 51634-0002
Start Marketing Date : 2000-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Samung Industrial Co., Ltd.
Registration Date : 2024-01-26
Registration Number : 20240126-209-J-1599
Manufacturer Name : Noramco, LLC
Manufacturer Address : 500 Swedes Landing Road Wilmington, Delaware 19801
NDC Package Code : 49812-0150
Start Marketing Date : 2010-06-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
NDC Package Code : 67509-006
Start Marketing Date : 2003-02-03
End Marketing Date : 2026-03-23
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
NDC Package Code : 51634-0003
Start Marketing Date : 2008-02-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
NDC Package Code : 51634-0002
Start Marketing Date : 2000-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 69988-0037
Start Marketing Date : 2012-04-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 62991-1410
Start Marketing Date : 2011-01-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 0406-8853
Start Marketing Date : 2012-12-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 0406-8873
Start Marketing Date : 2008-06-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 38779-0725
Start Marketing Date : 2014-08-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 51927-1008
Start Marketing Date : 2002-07-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Oxycodone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oxycodone, including repackagers and relabelers. The FDA regulates Oxycodone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oxycodone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Oxycodone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Oxycodone supplier is an individual or a company that provides Oxycodone active pharmaceutical ingredient (API) or Oxycodone finished formulations upon request. The Oxycodone suppliers may include Oxycodone API manufacturers, exporters, distributors and traders.
click here to find a list of Oxycodone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Oxycodone DMF (Drug Master File) is a document detailing the whole manufacturing process of Oxycodone active pharmaceutical ingredient (API) in detail. Different forms of Oxycodone DMFs exist exist since differing nations have different regulations, such as Oxycodone USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Oxycodone DMF submitted to regulatory agencies in the US is known as a USDMF. Oxycodone USDMF includes data on Oxycodone's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Oxycodone USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Oxycodone suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Oxycodone Drug Master File in Japan (Oxycodone JDMF) empowers Oxycodone API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Oxycodone JDMF during the approval evaluation for pharmaceutical products. At the time of Oxycodone JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Oxycodone suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Oxycodone Drug Master File in Korea (Oxycodone KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Oxycodone. The MFDS reviews the Oxycodone KDMF as part of the drug registration process and uses the information provided in the Oxycodone KDMF to evaluate the safety and efficacy of the drug.
After submitting a Oxycodone KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Oxycodone API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Oxycodone suppliers with KDMF on PharmaCompass.
A Oxycodone CEP of the European Pharmacopoeia monograph is often referred to as a Oxycodone Certificate of Suitability (COS). The purpose of a Oxycodone CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Oxycodone EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Oxycodone to their clients by showing that a Oxycodone CEP has been issued for it. The manufacturer submits a Oxycodone CEP (COS) as part of the market authorization procedure, and it takes on the role of a Oxycodone CEP holder for the record. Additionally, the data presented in the Oxycodone CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Oxycodone DMF.
A Oxycodone CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Oxycodone CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Oxycodone suppliers with CEP (COS) on PharmaCompass.
A Oxycodone written confirmation (Oxycodone WC) is an official document issued by a regulatory agency to a Oxycodone manufacturer, verifying that the manufacturing facility of a Oxycodone active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Oxycodone APIs or Oxycodone finished pharmaceutical products to another nation, regulatory agencies frequently require a Oxycodone WC (written confirmation) as part of the regulatory process.
click here to find a list of Oxycodone suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Oxycodone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Oxycodone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Oxycodone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Oxycodone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Oxycodone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Oxycodone suppliers with NDC on PharmaCompass.
Oxycodone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Oxycodone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Oxycodone GMP manufacturer or Oxycodone GMP API supplier for your needs.
A Oxycodone CoA (Certificate of Analysis) is a formal document that attests to Oxycodone's compliance with Oxycodone specifications and serves as a tool for batch-level quality control.
Oxycodone CoA mostly includes findings from lab analyses of a specific batch. For each Oxycodone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Oxycodone may be tested according to a variety of international standards, such as European Pharmacopoeia (Oxycodone EP), Oxycodone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Oxycodone USP).
LOOKING FOR A SUPPLIER?